ZIVO · Zivo Bioscience, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Nov 14, 2025
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Oct 27, 2023; bars on opposite sides are not compared.
The closing range begins at the captured split on Oct 27, 2023.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZIVO
this stock
Zivo Bioscience, Inc.
|
$16.53M | — | +468.6% | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +23.1% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +9.3% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$65.63B | +25.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.96B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.1%
- Net QoQ
- -500 sh
- Top holder
- CoreCap Advisors, LLC
Performance
Raw-price comparisons begin at the captured split on Oct 27, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZIVO | -47.7% | -74.7% | — | -75.2% | — |
| SPY | +0.8% | +10.7% | +6.2% | +8.7% | +18.8% |
| vs SPY | -48.5% | -85.4% | — | -83.9% | — |